📰 Access Pathway News
Page 10 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
May 26, 2023
Eisai and Biogen have submitted applications in Canada and the U.K. seeking the approval of lecanemab as a treatment for early Alzheimer's.
May 26, 2023
Eisai and Biogen have submitted applications in Canada and the U.K. seeking the approval of lecanemab as a treatment for early Alzheimer's.
May 25, 2023
The Pharmaceutical Journal from the Royal Pharmaceutical Society
May 23, 2023
Business Scoop provides news and views on Business and Markets from New Zealand
May 23, 2023
TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (A) protofibril antibody, for the treatment ...
May 22, 2023
TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid
May 22, 2023
STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
May 22, 2023
All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 ... | May 22, 2023
May 22, 2023
Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain - News - PharmaTimes
May 22, 2023
/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that they have submitted a Marketing Authorisation Application...